Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly
Yesterday 01:10
BRIEF-Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly June 24 (Reuters) - Abbisko Cayman Ltd 2256.HK:
THERAPEUTICS ENTERS STRATEGIC RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH ELI LILLY
ABBISKO THERAPEUTICS AND LILLY TO COLLABORATE ON MULTIPLE INNOVATIVE MEDICINE TARGETS
ABBISKO THERAPEUTICS DEEPENS R+D COLLABORATION WITH LILLY
ELIGIBLE FOR PAYMENTS UP TO US$1.9 BLN UNDER LILLY AGREEMENT
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)